AstraZeneca to present 19 abstracts at upcoming ESC Congress

The company states: “AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology, ESC, Congress from 25-28 August 2023, which includes data highlighting the opportunities for improved management in heart failure, and AstraZeneca’s leadership across the interconnectedness of chronic diseases. Among these abstracts will be sub-analyses from the DELIVER trial – a trial that has been pivotal in informing updates to medical guidelines. Notably, new late-breaking data from a pooled analysis of DELIVER and DAPA-HF trials assess the efficacy of Forxiga (dapagliflozin) versus placebo in HF patients whose eGFR levels fell below 25ml/min/1.73m2. The findings showed a marked elevation in the risks of CV outcomes in patients with deteriorating kidney function, further reinforcing the connection between heart failure and kidney disease. These patients appeared to benefit with continued treatment of Forxiga. New cardiopulmonary data from a sub-analysis of the DELIVER trial demonstrate the effects of Forxiga in patients with HF with preserved ejection fraction (pEF) and chronic obstructive pulmonary disease (COPD) – a common comorbidity that is associated with worse outcomes.2 In addition, findings from a multi-database cohort study, EXAcerbations of COPD and their OutcomeS in CardioVascular diseases (EXACOS-CV), illustrate increased COPD-driven cardiopulmonary risk including that of decompensated HF, acute coronary syndrome, arrhythmia, and ischemic stroke following a COPD exacerbation.”